EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Under the radar—frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies

Katherine E Francis iD, Sarah J Lord iD, Sandy Simon, Michael Friedlander iD, Val Gebski iD, John Simes iD, Chee Khoon Lee

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Katherine E Francis und 6 weiteren Autor:innen. Beteiligte Einrichtung: NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW 2050, Australia. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The current methods to capture and report adverse events (AEs) in clinical trials were developed in the era of cytotoxic chemotherapy and typically focused on higher grade AEs which may lead to severe harms. However, current cancer therapies including targeted agents, checkpoint inhibitors, and antibody drug conjugates are commonly administered for a prolonged duration and result in a cumulative symptom burden which may be inadequately reflected by the conventional approach to capture and reporting of AEs. Observations Existing approaches underestimate the chronic AE burden associated with extended exposure, particularly for low to moderate grade symptomatic AEs, and employ reporting methods that make comparison of similar treatments challenging. Furthermore, the specific AEs that may impact on treatment adherence and lead to dose modifications with oral self‑administered therapy are not typically reported. Conclusions and Relevance To address these limitations, we recommend: (1) a standardized approach to collection and reporting of patient reported AE data for symptomatic AEs, and reporting methods that incorporate information on the longitudinal characteristics of AEs including duration and trajectory; (2) accurately capturing adherence to oral agents; (3) transparent reporting of the AEs that result in dose reduction and treatment discontinuation in trials; (4) adoption of universal structured AE capture and reporting to allow meaningful comparison of the tolerability profile of therapies. As treatment options increase, optimizing capture and reporting of AEs to include lower grade yet troublesome AEs is essential to provide meaningful information on treatment tolerability to inform both clinicians and patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsHumansClinical Trials as Topic

Stichwörter der Autor:innen

adverse effectsadverse eventsclinical trialsoncologytolerabilitytoxicity

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW 2050, Australia.
  • Department of Medical Oncology, Wollongong Hospital, Wollongong, NSW 2500, Australia.
  • Department of Medical Oncology, Prince of Wales and Royal Hospital for Women, Randwick, NSW 2031, Australia.
  • School of Clinical Medicine, UNSW, Sydney 2052, Australia.
  • Department of Medical Oncology, St George Hospital, Kogarah, NSW 2217, Australia.

ORCID-Profile: Katherine E Francis, Sarah J Lord, Michael Friedlander, Val Gebski, John Simes

Zitieren

APA

Francis, K. E., Lord, S. J., Simon, S., Friedlander, M., Gebski, V., Simes, J., & Lee, C. K. (2025). Under the radar—frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies. The Oncologist. https://doi.org/10.1093/oncolo/oyaf230

Vancouver

Francis KE, Lord SJ, Simon S, Friedlander M, Gebski V, Simes J, et al. Under the radar—frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies. The Oncologist. 2025. doi:10.1093/oncolo/oyaf230

BibTeX
@article{Francis2025,
  author = {Francis, Katherine E and Lord, Sarah J and Simon, Sandy and Friedlander, Michael and Gebski, Val and Simes, John and Lee, Chee Khoon},
  title = {Under the radar—frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf230}
}
Kostenlos starten →